Palvella Therapeutics, Inc.
PVLA
$23.98
-$0.45-1.84%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 1.88M | 1.47M | 1.12M | 457.00K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 5.06M | 2.91M | 2.33M | 1.55M | |
| Operating Income | -5.06M | -2.91M | -2.33M | -1.55M | |
| Income Before Tax | -6.78M | -4.17M | -3.35M | -2.83M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -6.78M | -4.17M | -3.35M | -2.83M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -6.78M | -4.17M | -3.35M | -2.83M | |
| EBIT | -5.06M | -2.91M | -2.33M | -1.55M | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | -1.22 | -0.76 | -0.62 | -0.53 | |
| Normalized Basic EPS | -0.74 | -0.46 | -0.37 | -0.31 | |
| EPS Diluted | -1.22 | -0.76 | -0.62 | -0.53 | |
| Normalized Diluted EPS | -0.74 | -0.46 | -0.37 | -0.31 | |
| Average Basic Shares Outstanding | 5.72M | 5.72M | 5.72M | 5.72M | |
| Average Diluted Shares Outstanding | 5.72M | 5.72M | 5.72M | 5.72M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
